Page 43 - Read Online

Page 6 of 7 Sun et al. J Cancer Metastasis Treat 2019;5:80 I http://dx.doi.org/10.20517/2394-4722.2019.29

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Swoboda A, Nanda R. Immune checkpoint blockade for breast cancer. Cancer Treat Res 2018;173:155-65.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7-34.
3. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous
disease. Nat Rev Clin Oncol 2016;13:674-90.
4. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science
2011;331:1565-70.
5. Bayraktar S, Batoo S, Okuno S, Glück S. Immunotherapy in breast cancer. J Carcinog 2019;18:2.
6. Llibre A, Lopez-Macias C, Marafioti T, Mehta H, Partridge A, et al. LLT1 and CD161 expression in human germinal centers promotes B
cell activation and CXCR4 downregulation. J Immunol 2016;196:2085-94.
7. Llibre A, Klenerman P, Willberg CB. Multi-functional lectin-like transcript-1: a new player in human immune regulation. Immunol Lett
2016;177:62-9.
8. Roth P, Mittelbronn M, Wick W, Meyermann R, Tatagiba M, et al. Malignant glioma cells counteract antitumor immune responses through
expression of lectin-like transcript-1. Cancer Res 2007;67:3540-4.
9. Marrufo AM, Mathew SO, Chaudhary P, Malaer JD, Vishwanatha JK, et al. Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161)
interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells. Am J Cancer Res 2018;8:1050-63.
10. Heuck C, Weinhold N. Multiple Myeloma. New York: Springer; 2018.
11. Dai X, Cheng H, Bai Z, Li J. Breast cancer cell line classification and its relevance with breast tumor subtyping. J Cancer 2017;8:3131-41.
12. Malorni L, Shetty PB, De Angelis C, Hilsenbeck S, Rimawi MF, et al. Clinical and biologic features of triple-negative breast cancers in a
large cohort of patients with long-term follow-up. Breast Cancer Res Treat 2012;136:795-804.
13. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
14. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, et al. Sequence analysis of mutations and translocations across breast
cancer subtypes. Nature 2012;486:405-9.
15. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013;13:714-26.
16. Ding SL, Sheu LF, Yu JC, Yang TL, Chen BF, et al. Abnormality of the DNA double-strand-break checkpoint/repair genes, ATM, BRCA1
and TP53, in breast cancer is related to tumour grade. Br J Cancer 2004;90:1995-2001.
17. Shah SP, Roth A, Goya R, Oloumi A, Ha G, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers.
Nature 2012;486:395-9.
18. Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, et al. Neo-antigens predicted by tumor genome meta-analysis correlate with
increased patient survival. Genome Res 2014;24:743-50.
19. Zelefsky MJ, Eastham JA, Cronin AM, Fuks Z, Zhang Z, et al. Metastasis after radical prostatectomy or external beam radiotherapy for
patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol 2010;28:1508-13.
20. D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer:
a randomized trial. JAMA 2008;299:289-95.
21. Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, et al. Randomized trial comparing conventional-dose with high-dose conformal
radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of
radiology 95-09. J Clin Oncol 2010;28:1106-11.
22. Zhou Y, Bolton EC, Jones JO. Androgens and androgen receptor signaling in prostate tumorigenesis. J Mol Endocrinol 2015;54:R15-29.
23. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
24. Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol
2015;4:365-80.
25. Sullivan JL, Byron KS, Brewster FE, Purtilo DT. Deficient natural killer cell activity in x-linked lymphoproliferative syndrome. Science
1980;210:543-5.
26. Roder JC, Haliotis T, Klein M, Korec S, Jett JR, et al. A new immunodeficiency disorder in humans involving NK cells. Nature
1980;284:553-5.
27. Talmadge JE, Meyers KM, Prieur DJ, Starkey JR. Role of natural killer cells in tumor growth and metastasis: C57BL/6 normal and beige
mice. J Natl Cancer Inst 1980;65:929-35.
28. Gorelik E, Wiltrout RH, Okumura K, Habu S, Herberman RB. Role of NK cells in the control of metastatic spread and growth of tumor
cells in mice. Int J Cancer 1982;30:107-12.
29. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, et al. Activating receptors and coreceptors involved in human natural killer cell-
mediated cytolysis. Annu Rev Immunol 2001;19:197-223.
30. Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer 2016;16:7-19.
31. Thielens A, Vivier E, Romagne F. NK cell MHC class I specific receptors (KIR): from biology to clinical intervention. Curr Opin Immunol
2012;24:239-45.
32. Chiossone L, Dumas PY, Vienne M, Vivier E. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol 2018;18:671-88.